Technical analysis of Nkarta, Inc. (NKTX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as w...
Price Performance
| 1 month | +19.09% |
| 3 months | +0.35% |
| Year-to-date | +55.14% |
| 1 year | +50.26% |
| 3 years | +79.38% |
| 5 years | -90.83% |
52-Week Range
| 52-week High | $3.72 |
| 52-week Low | $1.70 |
| Avg Volume (90d) | 640K |
Technical Indicators
| SMA 50 | $2.59 |
| SMA 200 | $2.48 |
| Beta | 0.67 |
| 30-day Volatility (annualised) | 66.1% |
| Price vs SMA 50 | +10.7% |
| Price vs SMA 200 | +15.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $2.11 | |
| 2025-11 | $1.89 | -10.4% |
| 2025-12 | $1.85 | -2.1% |
| 2026-01 | $2.22 | +20.0% |
| 2026-02 | $2.70 | +21.6% |
| 2026-03 | $2.11 | -21.9% |
| 2026-04 | $2.77 | +31.3% |
| 2026-05 | $3.25 | +17.3% |
| 2026-06 | $2.83 | -12.9% |
| 2026-07 | $2.09 | -26.1% |
| 2026-08 | $2.71 | +29.7% |
| 2026-09 | $2.87 | +5.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $2.87 |
| Market Cap | $205M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.01 |
| EV / EBITDA | -2.60 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.30 |
| Current Ratio | 7.98 |